Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

French AFU Cancer Committee Guidelines - Update 2026-2028: Upper urinary tract urothelial tumors (UTUC).

Created on 19 Nov 2026

Authors

Mathieu Roumiguié, Priscilla Leon, Evanguelos Xylinas, Constance Thibault, Thomas Seisen, Doriane Prost, Yves Allory, Anne Sophie Bajeot, Benjamin Pradère, Yann Neuzillet, Gautier Marcq, François Audenet, Delphine Borchiellini, Pierre-Etienne Gabriel, Alexandra Masson-Lecomte, Morgan Roupret

Published in

The French journal of urology. Volume 36. Issue 11. Pages 103183.

Abstract

The purpose of this article is to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC).
A systematic Medline search for epidemiology, risk factors, diagnosis, prognosis, treatment options and follow-up of UTUC was performed between 2024 and 2026 to evaluate the available references and their levels of evidence.
UTUC is a rare malignancy with specific risk factors, including exposure to aristolochic acid and Lynch syndrome. Its diagnosis is based on the use of computed tomography urography and ureterorenoscopy with biopsies. A prognostic classification has been proposed to discriminate low- and high-risk lesions mainly on the basis of tumor grade (low/high) and imaging aspect (noninfiltrative/infiltrative). Tumor size (<2/≥2cm), focality (uni/multifocal), and hydronephrosis (absent/present) are more relative risk factors. The standard of care for low-risk patients is currently conservative treatment involving mainly ureterorenoscopy laser ablation, whereas radical nephroureterectomy (RNU) is advised for those with high-risk disease. Adjuvant treatments after RNU include the intravesical instillation of chemotherapy to decrease the risk of bladder recurrence and the delivery of platinum-based chemotherapy in pT2-T4 and/or pN+ patients. First-line treatment for metastatic UTUC is based on the use of a combination of enfortumab vedotin plus pembrolizumab. For unfit patients, platinum-based chemotherapy plus nivolumab followed by maintenance nivolumab in those with at least stable disease or platinum-based chemotherapy followed by maintenance avelumab in those with at least stable disease can be proposed. The surveillance regimen and schedule depend on the disease stage.
These updated guidelines will contribute to improving the management of patients diagnosed with UTUC.

PMID:
43051710
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement